Synaptogenix (NASDAQ:TAOX) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Synaptogenix (NASDAQ:TAOX) from a sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Synaptogenix has an average rating of “Sell”.

Synaptogenix Stock Performance

Shares of TAOX opened at $4.43 on Friday. The stock has a 50 day moving average price of $3.78 and a 200 day moving average price of $4.38. Synaptogenix has a one year low of $3.07 and a one year high of $10.00. The stock has a market capitalization of $33.14 million, a price-to-earnings ratio of -1.15 and a beta of 1.49.

Synaptogenix (NASDAQ:TAOX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.83) earnings per share for the quarter. Synaptogenix had a negative net margin of 2,153.97% and a negative return on equity of 128.51%. The firm had revenue of $0.09 million during the quarter.

About Synaptogenix

Synaptogenix, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc and adopted the Synaptogenix name as part of a corporate rebranding.